DC
ALXN

Deere & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Deere & Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,471
Closed -$1.81M – 1121
2016
Q2 		$1.81M Sell
15,471
-418
-3% -$59.3K 0.1% 185
2016
Q1 		$2.21M Buy
15,889
+1,456
+10% +$214K 0.12% 172
2015
Q4 		$2.75M Sell
14,433
-215
-1% -$37.6K 0.16% 135
2015
Q3 		$2.29M Buy
14,648
+9,247
+171% +$1.69M 0.14% 152
2015
Q2 		$976K Sell
5,401
-9,103
-63% -$1.57M 0.05% 402
2015
Q1 		$2.51M Sell
14,504
-6,945
-32% -$1.26M 0.13% 161
2014
Q4 		$3.97M Sell
21,449
-188
-0.9% -$34.8K 0.22% 100
2014
Q3 		$3.59M Buy
+21,637
New +$3.55M 0.2% 104

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Deere & Company's ALXN Position: Q3 2016 in Review

Deere & Company sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 15,471 shares — an estimated $1.81M sold.

Deere & Company first reported a position in ALXN in Q3 2014 and held it in 8 quarters. The position peaked at $3.97M in Q4 2014. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Deere & Company reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Deere & Company sold 15,471 Alexion Pharmaceuticals shares in Q3 2016, an estimated $1.81M.
  • Deere & Company first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Deere & Company's Alexion Pharmaceuticals position peaked at $3.97M in Q4 2014.
  • 517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Deere & Company's 13F filing for Q3 2016, filed 14 Nov 2016.